The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the stock has risen by around just 3%. This is not the type of investment ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.